Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gregory Ertl

Dermatology Yuma, AZ Medical Doctor

NPI 1427051184 CMS profile 64816

350 W Catalina Dr, Yuma, AZ 85364

Open in the dashboard

General payments

$1,571

80 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gregory Ertl of Yuma, AZ is reported in the CMS Open Payments database as having received $1,571 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $166 8
2022 General $263 14
2021 General $411 18
2020 General $343 19
2019 General $388 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Ertl
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Gregory Ertl were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Gregory Ertl Dermatology median Middle half National median
2019 $388 $454 $129–$1,240 $163
2020 $343 $235 $81–$756 $114
2021 $411 $377 $108–$1,108 $132
2022 $263 $514 $143–$1,391 $149
2023 $166 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $467 27 payments
  2. Janssen Biotech, Inc. $200 6 payments
  3. Pfizer Inc. $183 9 payments
  4. Sun Pharmaceutical Industries Inc. $133 7 payments
  5. LEO Pharma Inc. $130 7 payments
  6. STRATA Skin Sciences, Inc. $118 5 payments
  7. Novartis Pharmaceuticals Corporation $86 5 payments
  8. DUSA Pharmaceuticals, Inc. $69 3 payments
  9. Lilly USA, LLC $56 3 payments
  10. Genzyme Corporation $36 2 payments
  11. Other $94 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,471 79 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2023
  1. HUMIRA $329 20 payments
  2. SKYRIZI $243 14 payments
  3. EUCRISA $183 9 payments
  4. TREMFYA $160 4 payments
  5. CIBINQO $131 6 payments
  6. XTRAC $96 2 payments
  7. ENSTILAR $81 5 payments
  8. BLU-U Dermatology $79 4 payments
  9. LEVULAN KERASTICK $69 3 payments
  10. BLU-U Dermatology $69 3 payments
  11. Other $580 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

33

Median for Specialist: 51

Drug cost

$766

Median for Specialist: $1,236

Branded share of claims

0%

Median for Specialist: 21.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Betamethasone Valerate Generic 11 $396
Triamcinolone Acetonide Generic 22 $370

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,049 Part D prescribers listed as Specialist; they describe a distribution and say nothing about conduct.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record